Research and Development

An experienced pharmaceutical development team

Research and Development

At GMPO our research and development strategy is focused on the patient. Our mission is to identify and develop innovative therapies for patients, in the hope of making a meaningful difference to their lives.

We only work in rare diseases with an unmet medical need. There are over 7,000 known rare diseases. We have selected to develop our first product in Wilson’s Disease, a disease affecting 1 in every 30,000 of the population. Cuprior is an innovative formulation, that has the potential to offer new options to patients.

We have a network of world experts and work with scientists, academic institutions and companies with innovative technologies and products to enable their development and commercialization.

Cuprior Development

EU – Patients intolerant to D-Penicillamine
US – Patients intolerant to D-Penicillamine

RegionPreclinicalPhase 1Phase 2Phase 3FilingApproval
EU
USA
EU
Approval Stage
US
Phase 3 Development

Cuprior Development Plan

Indication / study
Phase III Head to Head Study
WD real-world evidence

2020

Q1Q2Q3Q4
Chelate trial 36-week efficacy analysis
Global Wilson’s Disease Product Registry

2021

Q1Q2Q3Q4
Extension continues up to 60 weeks
 

Phase III Head to Head Study

2020 Q1 - 2020 Q3: Chelate trial 36-week efficacy analysis
2020 Q4 - 2021 Q3: Extension continues up to 60 weeks

WD real-world evidence

2020 Q3 - 2021 Q4: Global Wilson’s Disease Product Registry

Get In Touch

Find out more about GMPO, who we are and what we do.

Start typing and press Enter to search

Hello. Add your message here.